Polaris HealthTech Unveils Wearable ECG Patch After $30M Series B

Tech · 5 min read

The financing was led by LifeSpan Ventures with participation from clinical-focused investors. Polaris will use proceeds to pursue FDA clearance and expand clinical trials across several health systems.

The ECG patch adheres for 7–10 days and streams encrypted waveform snippets to Polaris’ cloud, where AI models flag potential arrhythmias and irregular conduction patterns. Clinicians receive prioritized alerts with annotated waveforms for review.

Physician partners highlight improved diagnostic yield for intermittent arrhythmias compared to periodic Holter monitoring. Polaris emphasizes clinician oversight and provides workflow integrations with EHR systems for streamlined follow-up.

Regulatory approval and reimbursement pathways remain the next hurdles. Polaris is pursuing both traditional CPT coding and value-based contracts with health systems that show improved outcomes and reduced readmissions.